Jacobs & Co. CA Has $23.86 Million Stock Holdings in Eli Lilly and Company $LLY

Jacobs & Co. CA raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,605 shares of the company’s stock after acquiring an additional 793 shares during the period. Eli Lilly and Company makes up 2.4% of Jacobs & Co. CA’s portfolio, making the stock its 8th biggest holding. Jacobs & Co. CA’s holdings in Eli Lilly and Company were worth $23,857,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of LLY. WestEnd Advisors LLC lifted its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department lifted its stake in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on LLY shares. Leerink Partners reiterated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 30th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Finally, Cantor Fitzgerald dropped their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $941.35.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $754.90 on Friday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $714.48 billion, a PE ratio of 49.34, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The firm has a 50-day moving average price of $741.03 and a 200 day moving average price of $777.36.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 39.22%.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.